RAMM PharmaXCNQ:RAMM EV-to-FCF is -0.24 as of Jul. 02, 2026. The stock has 4 warning signs investors should review. Among 561 Drug Manufacturers companies, RAMM Pharma ranks worse than 178252.94% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, RAMM Pharma's Enterprise Value is C$0.27 Mil.
RAMM Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 was C$-1.14 Mil. Therefore, RAMM Pharma's EV-to-FCF for today is -0.24.
The historical rank and industry rank for RAMM Pharma's EV-to-FCF or its related term are showing as below:
XCNQ:RAMM'
s EV-to-FCF Range Over the Past 10 Years
Min: -28.05 Med: -1.29 Max: 0.31
Current: -0.76
During the past 8 years, the highest EV-to-FCF of RAMM Pharma was 0.31. The lowest was -28.05. And the median was -1.29.
XCNQ:RAMM's EV-to-FCF is ranked worse than 100% of 561
companies
in the Drug Manufacturers industry
Industry Median: 20.16
vs XCNQ:RAMM: -0.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RAMM Pharma's PE Ratio (TTM) for today is calculated as:
RAMM Pharma's share price for today is C$0.01.
RAMM Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.072.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
RAMM Pharma EV-to-FCF Related Terms
RAMM Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for RAMM Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAMM Pharma EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where RAMM Pharma's EV-to-FCF falls into.
RAMM Pharma's current Enterprise Value is C$0.27 Mil.
RAMM Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAMM Pharma (XCNQ:RAMM) has a EV-to-FCF of -0.24 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on RAMM Pharma and its competitors. According to the industry distribution chart, RAMM Pharma ranks #999999 out of 561 companies in the Drug Manufacturers industry.
Is RAMM Pharma's EV-to-FCF too high?
RAMM Pharma's current EV-to-FCF is -0.24. Based on the distribution chart, RAMM Pharma ranks #999999 out of 561 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does RAMM Pharma's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RAMM Pharma ranks #999999 out of 561 companies for EV-to-FCF. This places RAMM Pharma in the lower half of its industry. The industry median EV-to-FCF is 20.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.16, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on RAMM Pharma and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RAMM Pharma's current EV-to-FCF is -0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current EV-to-FCF is -0.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current EV-to-FCF is -0.24 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RAMM has been successfully added to your 